Erythropoietin in cardiac disease: Effective or harmful?

Journal of Cardiovascular Medicine

Volumn 14, Issue 12, 2013, Pages 870-878

  Mastromarino, Vittoria ^a   Musumeci, Maria B ^a   Conti, Elena ^a   Tocci, Giuliano ^b   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Anemia; Cerebrovascular thromboembolism; Congestive heart failure; Erythropoietin; Myocardial infarction

Indexed keywords

ANTIANEMIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DRUG TOLERABILITY; HEART DISEASE; HEART FAILURE; HEMATOPOIESIS; HUMAN; IRON THERAPY; MEDICAL LITERATURE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PILOT STUDY; PROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 84890127361     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328362c6ae     Document Type: Review

References (82)

1. Henry DH, Bowers P, Romano MT, et al. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004; 164:262-276.
2. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the bloodbrain barrier to protect against experimental brain injury. PNAS 2000; 97:10526-10531.
3. CelikF M. Gökmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. PNAS 2002; 99:2258-2263.
4. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the longacting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110:1006-1012.
5. Patel NSA, Sharples EJ, Cuzzocrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004; 66:983-989.
6. van der Meer P, Voors AA, Lipsic E, et al. Erythropoietin in cardiovascular diseases. Eur Heart J 2004; 25:285-291.
7. Mastromarino V, Volpe M, Musumeci MB, et al. Erythropoietin and the heart: facts and perspectives. Clin Sci (Lond) 2011; 120:51-63.
8. Löw-Friedrich I, Grützmacher P, März W, et al. Long-term echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin. Blood Purif 1990; 8:272-278.
9. Pascual J, Teruel JL, Moya JL, et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35:280-287.
10. Goldberg N, Lundin AP, Delano B, et al. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 1992; 124:424-427.
11. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6:1-4.
12. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. PNAS 2003; 100:4802-4806.
13. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112:999-1007.
14. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. PNAS 2003; 100:11612-11617.
15. van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemiareperfusion injury. Eur J Heart Fail 2004; 6:853-859.
16. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004; 279:20655-20662.
17. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004; 44:473-479.
18. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005; 100:397-403.
19. van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005; 46:125-133.
20. Liu X, Xie W, Liu P, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemiareperfusion. Life Sci 2006; 78:2255-2264.
21. Lipsic E, van der Meer P, Voors AA, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20:135-141.
22. Ferrario M, Arbustini E, Massa M, et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 2011; 147:124-131.
23. Ozawa T, Toba K, Suzuki H, et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction: randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010; 74:1415-1423.
24. Taniguchi N, Nakamura T, Sawada T, et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 2010; 74:2365-2371.
25. Ludman AJ, Yellon DM, Hasleton J, et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart 2011; 97:1560-1565.
26. Voors AA, Belonje AM, Zijlstra F, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010; 31:2593-2600.
27. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011; 305:1863-1872.
28. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute STsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3:3408-3413.
29. Prunier F, Bière L, Gilard M, et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J 2012; 163:200e1-207e1.
30. Liem A, van de WoestijneF AP. Bruijns E, et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes: results from a pilot study. Int J Cardiol 2009; 13:1285-1287.
31. Binbrek AS, Rao NS, Al Khaja N, et al. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 2009; 104:1035-1040.
32. Suh JW, Chung WY, Kim YS, et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol 2010; 149:216-220.
33. Li J, Xu H, Gao Q, Wen Y. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review. Eur J Clin Pharmacol 2012; 68:469-477.
34. Gao D, Ning N, Niu X, et al. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Am Heart J 2012; 164:715-727.
35. Kristensen J, Maeng M, Rehling M, et al. Lack of acute cardioprotective effect from preischaemic erythropoietin administration in a porcine coronary occlusion model. Clin Physiol Funct Imaging 2005; 25:305-310.
36. Talan MI, Ahmet I, Lakatta EG. Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window? PLoS One 2012; 7:e34819.
37. van der Meer P, van Veldhuisen DJ. Acute coronary syndromes: the unfulfilled promise of erythropoietin in patients with MI. Nat Rev Cardiol 2011; 8:425-426.
38. Suh JW, Yoon YE, Oh IY, et al. A single-center prospective randomized controlled trial evaluating the safety and efficacy of Intra Coronary Erythropoietin delivery Before Reperfusion: Gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the 'ICEBERG Trial'. Contemp Clin Trials 2013; 35:145-150.
39. Minamino T, Toba K, Higo S, et al. Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): a randomized controlled clinical trial. Cardiovasc Drugs Ther 2012; 26:409-416.
40. Andreotti F, Agati L, Conti E, et al. Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in AcuteMyocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). J Thromb Thrombolysis 2009; 28:489-495.
41. van der Meer O, van Veldhuisen DJ. Anaemia and renal dysfunction in chronic heart failure. Heart 2009; 95:1808-1812.
42. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52:818-827.
43. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006; 26:296-306.
44. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005; 26:2232-2237.
45. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994; 74:468-473.
46. van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44:63-67.
47. George J, Patal S, Wexler D, et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure. Comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005; 165:1304-1309.
48. Jensen JD, EiskjaerF H. Bagger JP, Pedersen EB. Elevated level of erythropoietin in congestive heart failure relationship to renal perfusion and plasma renin. J Intern Med 1993; 233:125-130.
49. Lipsic E, Westenbrink BD, van der Meer P, et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008; 10:22-29.
50. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006; 48:176-184.
51. Latini R, Brines M, Fiordaliso F. Do nonhemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 2008; 13:415-423.
52. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999; 93:2627-2636.
53. Kawachi K, Iso Y, Sato T, et al. Effects of erythropoietin on angiogenesis after myocardial infarction in porcine. Heart Vessels 2012; 27:79-88.
54. Ueda K, Takano H, Niitsuma Y, et al. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest 2010; 120:2016-2029.
55. Wu H, Lee SH, Gao J, et al. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999; 126:3597-3605.
56. Bahlmann FH, DeGroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64:1648-1652.
57. Westenbrink BD, Lipsic E, van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularisation. Eur Heart J 2007; 28:2018-2027.
58. Li Y, Takemura G, Okada H, et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006; 71:684-694.
59. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35:1737-1744.
60. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37:1775-1780.
61. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107:294-299.
62. Palazzuoli A, Silverberg DS, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152:1096e9-1096e15.
63. Palazzuoli A, Silverberg DS, Iovine F, et al. Effects of b-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; 154:645e9-645e15.
64. Parissis JT, Kourea K, Panou F, et al. Effects of darbepoetina on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008; 155:751e1-751e7.
65. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49:753-762.
66. Kourea K, Parissis JT, Farmakis D, et al. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2008; 15:365-369.
67. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized, doubleblind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007; 28:2208-2216.
68. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117:526-535.
69. Kotecha D, Ngo K, Walters JA, et al. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J 2011; 161:822e2-831e2.
70. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368:1210-1219.
71. McMurray JJ, Anand IS, Diaz R, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009; 11:795-801.
72. McMurray JJ, Anand IS, Diaz R, et al. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). Eur J Heart Fail 2013; 15:334-341.
73. Bergmann MW, Haufe S, von Knobelsdorff-Brenkenhoff F, et al. A pilot study of chronic, low-dose epoetin-{beta} following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with symptomatic ischaemic heart failure. Eur J Heart Fail 2011; 13:560-568.
74. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924.
75. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 1 studies including 9353 patients. J Natl Cancer Inst 2006; 98:708-714.
76. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
77. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 1 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019-2032.
78. Skali H, Parving HH, Parfrey PS, et al. Stroke in patients with type 1 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoietin alfa: the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) experience. Circulation 2011; 124:2903-2908.
79. FDA Drug Safety Communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm (accessed 1 June 2013).
80. Tehrani F, Dhesi P, Daneshvar D, et al. Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis. Cardiovasc Drugs Ther 2009; 23:511-518.
81. Klapholz M, Abraham WT, Ghali JK, et al. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Fail 2011; 11:1071-1077.
82. van der Meer P, Groenveld HF, Januzzi JL Jr, van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a metaanalysis. Heart 2009; 95:1309-1314.